Responsibilities of sponsors are limited in premature discontinuation of trials.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Odon device for instrumental vaginal deliveries: results of a medical device pilot clinical study.Reproductive health · 2018
   Trial
2. Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?Journal of interventional cardiology · 2013
   Trial
3. Stopping trials early for commercial reasons: the risk-benefit relationship as a moral compass.Journal of medical ethics · 2005
   Review

Corrections and comments

• Comment on
  Societal responsibilities of clinical trial sponsors. Lack of commercial pay off is not a legitimate reason for stopping a trial.2001
• Comment on
  Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility.2001

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as